Clinical trial · Interventional
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy
NCT01102335CI-TRIAL-00003362TACEHBVunknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Telbivudine | Drug | — | UNRESOLVED |
| Transcatheter arterial chemoembolization (TACE) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Telbivudine
- interventionNames
- Procedure: Transcatheter arterial chemoembolization (TACE)
- Drug: Telbivudine
- type
- ACTIVE_COMPARATOR
- label
- TACE only
- interventionNames
- Procedure: Transcatheter arterial chemoembolization (TACE)
Primary outcomes (1)
- measure
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- timeFrame
- 6 months
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * hepatocellular carcinoma * treated with transcatheter arterial chemoembolization (TACE) * HBVDNA \> 10\^3copies/mL, including alanine aminotransferase (ALT) normal patient * expected survive time \> 1 year * HBV marker positive (anyone of HbsAg, HbsAb, HbeAg, HbeAb and HbcAb) Exclusion Criteria: * antiviral therapy history * alanine aminotransferase (ALT) \>400 U/L * serum total bilirubin \> 50 μmol/L * HBVDNA \> 10\^9copies/mL * extrahepatic metastasis or main portal vein embolus * apparent cardiac or pulmonary dysfunction * liver function: Child B or Child C * HCV infection
References
Publications (0)
Data not yet available
No reference posted for this study.